Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIHRas cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: Glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.

Gaglio, D., Valtorta, S., Ripamonti, M., Bonanomi, M., Damiani, C., Todde, S., et al. (2016). Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study. ONCOTARGET, 7(32), 52017-52031 [10.18632/oncotarget.10470].

Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study

Valtorta, Silvia;BONANOMI, MARCELLA;DAMIANI, CHIARA;TODDE, SERGIO CAMILLO;MASTROIANNI, FABRIZIA;GILARDI, MARIA CARLA;COLANGELO, ANNA MARIA;ALBERGHINA, LILIA;MORESCO, ROSA MARIA
2016

Abstract

Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIHRas cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: Glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.
Articolo in rivista - Articolo scientifico
Metabolic rewiring; Metabolomics-mass-spectrometry; Oncogenic-K-ras; PET-imaging; Tumor;
Tumor, metabolic rewaring, PET imaging, metabolomics-mass-spectrometry, oncogenic-K-ras
English
2016
7
32
52017
52031
open
Gaglio, D., Valtorta, S., Ripamonti, M., Bonanomi, M., Damiani, C., Todde, S., et al. (2016). Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study. ONCOTARGET, 7(32), 52017-52031 [10.18632/oncotarget.10470].
File in questo prodotto:
File Dimensione Formato  
10281-119849.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 9.95 MB
Formato Adobe PDF
9.95 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/119849
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 12
Social impact